Navigation Links
OncoGenex Technologies Announces Phase II Data of OGX-011 in,Metastatic Breast Cancer at American Association for Cancer,Research 2007 Annual Meeting

econd cycle.

OGX-011 is designed to specifically inhibit the production of the cell-survival protein, clusterin. Clusterin production is associated with treatment resistance in many cancers and in response to various cancer treatments, including hormone ablation therapy, chemotherapy and radiation therapy. Preclinical studies have shown that inhibition of clusterin can disable the tumor cell's adaptive defences, render the tumor cells susceptible to attack with a variety of cancer therapies, including chemotherapy, and facilitate tumor cell death. OncoGenex is developing OGX-011 in collaboration with Isis Pharmaceuticals Inc.

The study was sponsored by the National Cancer Institute of Canada - Clinical Trials Group with support provided by OncoGenex Technologies Inc.

About OncoGenex

OncoGenex is committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex currently has three product candidates in development: OGX-011, OGX-427 and OGX-225. These product candidates are designed to selectively inhibit the production of proteins that are associated with treatment resistance and that are over-produced in response to a variety of cancer treatments. OncoGenex' aim in targeting these particular proteins is to disable the tumor cells' adaptive defenses, render the tumor cells susceptible to attack with a variety of cancer therapies including chemotherapy, and facilitate tumor cell death. More information on OncoGenex and the company's pipeline is available at www.oncogenex.ca.

CONTACT: OncoGenex Contact: Scott Cormack, President & CEO, (604) 630-5400; Media Contact: Jason Spark, Porter Novelli Life Sciences, (619) 849-6005

CONTACT: OncoGenex Contact: Scott Cormack, President & CEO, (604)630-5400; Media Contact: Jason Spark, Porter Novelli Life Sciences, (619)849-6005

Terms
'"/>




Page: 1 2 3 4

Related medicine technology :

1. OncoGenex and Isis Announce OGX-011 Data to be Presented at ASCO
2. Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
3. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
4. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
5. Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction
6. Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at 20th International Conference on Antiviral Research Meeting
7. Micell Technologies Presents Data on Novel Drug-Eluting Stents
8. AVAX Technologies Presents Results of Phase I-II M-Vax Trial at Annual Meeting of American Association for Cancer Research
9. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:10/8/2008)...atments for Spinal Cord, Other Nerve,Injuries -, ...protein that enables,nerve cells to communicate wi...developing nervous system. Research into how that ...rve cells may provide a basis for eventual,treatme...ous system,including spinal cord injury., "This ...
(Date:10/8/2008)...continued and Headcount to be Reduced, Summary: Ge...; Zanolimumab Program to be Discontinued and the ... Employees, COPENHAGEN, October 8 /P...unced today that it is discontinuing development o...sult of a portfolio review and,assessment of the o...
(Date:10/8/2008)...TAXUS(R) Element(TM) Platinum Chromium ... /- Boston Scientific,Corpo...ompleted enrollment in,the PERSEUS trial, designed...R) Element(TM) paclitaxel-eluting coronary stent. ...,500 patients at 100 U.S. and,international center...
(Date:10/8/2008)... -- Vical Incorporated (Nasdaq: VICL ),today is p...al data,demonstrating that the company,s Vaxfectin... protein-based infectious disease vaccines and,pep...m.D., Ph.D., Vical,s,Senior Vice President of Prod...esday, October 8, at the World Vaccine Congress (L...
Breaking Medicine Technology:Protein Shown to Play a Key Role in Normal Development of Nervous System 2Protein Shown to Play a Key Role in Normal Development of Nervous System 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Saving Lives of Florida Residents Who Develop Skin Cancer Each Year 3A The Key is Early Detection and Treatment 252 1Saving Lives of Florida Residents Who Develop Skin Cancer Each Year 3A The Key is Early Detection and Treatment 252 2CABI helps phase out dangerous pesticide in EU 356 1CABI helps phase out dangerous pesticide in EU 356 2Microbiotic technology developed for microinjection of zebrafish embryos 1069 1Family Dinners Shape Healthier Eating Habits 1065 1
...--May 15, 2007 - Synthetic Blood,International, In...,a statistical analysis of its Phase IIa study wit...ury. In line with preliminary,study results announ...d that the primary endpoint of increasing patients... met. Data also show a,decrease in patient glucose...
... 17, 2007 - Salix,Pharmaceuticals, Ltd. (NASDAQ:SL...r-initiated trials related to the Company,s produc...2007, which will be,held May 19-24, 2007. Digestiv...prestigious meeting in the world for the GI,profes...ysicians,researchers and academics from around th...
Other Medicine Technology:Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 2Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 3Salix Pharmaceuticals Previews Digestive Disease Week 2007 2Salix Pharmaceuticals Previews Digestive Disease Week 2007 3Salix Pharmaceuticals Previews Digestive Disease Week 2007 4Salix Pharmaceuticals Previews Digestive Disease Week 2007 5
(Date:10/10/2008)...10 /PRNewswire-FirstCall/ -- Hologic, Inc.,(Nasdaq...upplier of premium,diagnostics, medical imaging sy...he healthcare needs of women, today announced plan...erating results on Tuesday, November 11,2008 afte...anagement will,host a conference call on Tuesday, ...
(Date:10/10/2008)... Upon the completion of a highly successful CIO Fi...roudly announces their next business technology ga...ology executives in healthcare. CDM Media has conf...-12, 2009 at the Four Seasons Resort in Scottsdale...EB) October 11, 2008 -- Upon the completion of a h...
(Date:10/10/2008)... 10 /PRNewswire/ -- NuView Life Sciences Inc.,(NuV... Sciences Inc.,(Trace), including operations of th...lities in Denton, Texas. The Trace facility produc...nd Thallium-201 used in,molecular imaging and nucl... stated that "We are confident that by improving o...
(Date:10/10/2008)...Calif., Oct. 10 /PRNewswire/ -- A senior citizen,s...ountains in a small,plane. The high-flying adventu.... The thrill came from a last-wish program through...nior Living, where Heden was a patient.,Called Go ...it has helped,many realize a special activity at t...
Breaking Medicine News(10 mins):Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2Health News:CIO Healthcare Summit Announces Dates and VIP Delegates 2Health News:Deck of Cards is More Than a Game: Integral in Silverado Hospice Care 2
...ork-Presbyterian Hospital/Weill Cornell Medical Ce...nts the ability of an antibody to directly target ...ing healthy tissues unharmed. The Phase I clinica..., targeted to the prostate specific membrane antig...
...y 40% of the doctors in one Russian city have late...ho work in TB clinics. The research has been publi...oblem worldwide. Russia is one country where it is... third of the world's population are infected with...
... standard breast cancer therapy drug tamoxifen, to...s by almost one-fifths. Publishing their finding... Dr. Francesco Boccardo of the National Cancer Res... changing treatments tracks to exemestane after 2 ...
...r from persistent iron overload has been cleared. ...um. Patients suffering from a rare genetic condit...se need regular blood transfusions. Generally thes... at nights by needle and pump which lasts for arou...
Other Medicine News:Health News:First Treatment to Directly Target Tumor Blood Supply 2Health News:First Treatment to Directly Target Tumor Blood Supply 3Health News:New Drug Therapy for Breast Cancer Offers Hope 2
...dy (IgG) Test is a semiquantitative enzyme immunoa...cant IgG antibodies to M. pneumoniae between acute...should not be used for specimens found reactive wi... Test and is not intended for qualitative (one spe...
...unoassay (EIA) that detects IgG antibodies to Epst...arr early nuclear antigen (EBV-EBNA), cytomegalovi...n with Mono-M Test it is an aid in the serodiagnos...ve serodiagnosis of CMV or Toxoplasma mononucleosi...
The ImmunoDOT TORCH Test is an enzyme immunoassay (EIA) procedure intended for determining the presence of antibodies to Toxoplasma gondii, rubella virus, cytomegalovirus and herpes simplex virus in
...e enzyme immunoassays (EIA) for the presumptive de... IgM, respectively) in serum. Equivocal or positiv...with a standardized western blot procedure. These ...ical diagnosis of B. burgdorferi infection (Lyme d...
Medicine Products: